Sirolimus (rapamycin) inhibits mitogen-induced stimulation of protein synthesis in primary lymphocytes.
Wyeth-Ayerst Research, Princeton, NJ 08543-8000, USA.
C C
CC
Bansbach
D
D
Wancio
S N
SN
Sehgal
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D004247:DNA / Q000096:biosynthesis; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008934:Mitogens / Q000037:antagonists & inhibitors*; D010835:Phytohemagglutinins / Q000494:pharmacology; D011090:Polyenes / Q000494:pharmacology*; D014176:Protein Biosynthesis; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D020123:Sirolimus; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism*
D000903:Antibiotics, Antineoplastic; D008934:Mitogens; D010835:Phytohemagglutinins; D011090:Polyenes; D011500:Protein Synthesis Inhibitors; D004247:DNA; D020123:Sirolimus